Swedish AB vaccine succeeds in creating antibodies
Thursday 07 June 2012
Researchers from Karolinska Institutet in Sweden have successfully completed an initial human trial of a prototype amyloid beta vaccine called CAD106.
A team led by Prof Bengt Winblad tested the vaccine on 46 volunteers aged 50-80 and diagnosed with mild to moderate Alzheimer's disease. A control group of 12 people received a placebo. After a year, 82% of those who received the drug developed antibodies, a sign that their immune defenses had responded to the toxic protein.
The researchers are now planning a larger test.